about
We are ageingProfile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patientsAttenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory ActivityPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.The impact of dietary energy intake on cognitive aging.Exenatide once weekly: clinical outcomes and patient satisfaction.Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients.Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitusProfile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability.Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series.Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.Molecular cloning and heterologous expression in Pichia pastoris of X-prolyl-dipeptidyl aminopeptidase from basidiomycete Ustilago maydis.[Dipeptidyl peptidase IV in inflammatory bowel diseases (DPP IV/CD26)].
P2860
Q21284533-115EBFA6-4796-48DE-A778-4F1F9AA1F447Q26824239-358F33D9-EDDE-4E59-A8DE-67C0B9074DE2Q27315825-2716B993-9929-4908-9429-1E95075F15B9Q30249371-CB80D002-C641-4000-80DA-8D2B33C0838BQ33868403-2B89CB88-AA31-49AE-BE14-7A2F30D1B2F5Q34144380-9095CAF2-0601-413E-A842-1FF9BD32B194Q35111555-766DC3B5-B01C-434C-BB88-00544A97B477Q35564083-238114F7-9E03-46C2-A9C5-F8BF2336B427Q35622245-6CDF0DC9-A591-4577-9D38-D373B8D5957FQ36960161-BDA8EE43-131D-4217-9402-FD409CE3930FQ37015654-D9AC42AF-6B0B-4100-B453-87C36D0CE383Q37948831-34B4566E-93B0-4C95-BC23-AEC3CD063BB6Q38036769-DDA20FFF-57F3-463C-9DC3-E262BAEC8AB3Q38546598-F37F7FC8-074F-4FC2-B4F5-60BC40F11EF9Q38833194-81C2E178-218D-48CA-BBDD-6FA3A26F434AQ45104779-00813607-03CA-4FFE-83FC-310431D797FEQ53807699-5FE0CC4F-06A6-4137-83DE-A57839ECCD17
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
DPP-4 inhibitors in clinical practice.
@en
DPP-4 inhibitors in clinical practice.
@nl
type
label
DPP-4 inhibitors in clinical practice.
@en
DPP-4 inhibitors in clinical practice.
@nl
prefLabel
DPP-4 inhibitors in clinical practice.
@en
DPP-4 inhibitors in clinical practice.
@nl
P2093
P2860
P356
P1476
DPP-4 inhibitors in clinical practice
@en
P2093
Anna I Palalau
Anthony H Barnett
Milan K Piya
P2860
P304
P356
10.3810/PGM.2009.11.2079
P407
P577
2009-11-01T00:00:00Z